OTTAWA - A commander of a patrol frigate in the Royal Canadian Navy has been relieved of his duty mid-deployment due to what ...

Biosciences stock, lowering the price target to $163 from the previous $172 while maintaining a Buy rating. The revision follows a reevaluation of the company's sales projections for its leading ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...